Progen Co., Ltd. (XKON:296160)

South Korea flag South Korea · Delayed Price · Currency is KRW
7,900.00
+220.00 (2.86%)
At close: Dec 5, 2025
19.88%
Market Cap 112.89B
Revenue (ttm) 450.00M
Net Income (ttm) -15.25B
Shares Out 14.29M
EPS (ttm) -3,307.00
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 13,424
Average Volume 20,181
Open 7,800.00
Previous Close 7,680.00
Day's Range 7,700.00 - 7,920.00
52-Week Range 4,515.00 - 9,970.00
Beta -1.63
RSI 65.65
Earnings Date n/a

About Progen

Progen Co., Ltd., a biotechnology company, engages in platform-based drug discovery and development activities. The company’s NTIG platform technology is used for the development of anti-cancer and immune disease treatments. It develops PG-102 for the treatment of obesity with T2DM to control blood sugar, improve metabolic function, and reduce weight in the gastrointestinal tract and adipocytes. The company was founded in 1998 and is based in Seoul, South Korea. [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 1998
Country South Korea
Stock Exchange Korea New Exchange
Ticker Symbol 296160
Full Company Profile

Financial Performance

In 2022, Progen's revenue was 450.00 million, a decrease of -67.36% compared to the previous year's 1.38 billion. Losses were -15.25 billion, 135.0% more than in 2021.

Financial Statements

News

There is no news available yet.